diabetestalk.net

Metformin And Bladder Tumor

Nephro-urology Monthly

Nephro-urology Monthly

1 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran * Corresponding author: Alireza Ghadian, Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-2181262073, E-mail: [email protected] Nephro-Urology Monthly: May 2016, 8 (3) ; e30261 Published Online: March 19, 2016 To Cite: Heidari F, Abbas Zade S, Mir Hosseini S H, Ghadian A. Metformin for the Prevention of Bladder Cancer Recurrence: Is it Effective?, Nephro-Urol Mon. 2016 ;8(3):e30261. doi: 10.5812/numonthly.30261 . Background: Many methods have been used for preventing and reducing recurrences of bladder cancers. In recent years, some investigators have examined the use of metformin for this purpose. First lines of evidence have shown that metformin inhibits cancer cell growth and prevents cancer occurrence in patients with type 2 diabetes. Objectives: This study is designed to assess metformin usage in the prevention of bladder cancer recurrence after the trans-urethral resection of a bladder tumor (TUR-T). Patients and Methods: In the present study, metformin was administered in the treatment of 32 patients with a history of bladder cancer, and their results were compared with those of 33 patients with bladder cancer recurrence (placebo group). Patients in the metformin group received 1000 mg metformin (2 tablets 500 mg) for 1 year. Frequency of tumor recurrence was calculated and compared with the placebo group. Results: There was no statistical difference between the 2 groups with respect to the recurrence rate (P > 0.05). Although the recurrence interval was longer for the metformin group, this increase was not statistical significant (P > 0.05). Furthermore, tumor recurrence had no correlation with se Continue reading >>

Metformin And Gefitinib Cooperate To Inhibit Bladder Cancer Growth Via Both Ampk And Egfr Pathways Joining At Akt And Erk

Metformin And Gefitinib Cooperate To Inhibit Bladder Cancer Growth Via Both Ampk And Egfr Pathways Joining At Akt And Erk

Article | Open Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk Scientific Reports volume 6, Articlenumber:28611 (2016) EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The efficacy of gefitinib, a well-known EGFR tyrosine kinase inhibitor, combined with metformin was assessed on bladder cancer and underlying mechanisms were explored. This drug combination induced a strong anti-proliferative and anti-colony forming effect and apoptosis in bladder cancer cell lines. Gefitinib suppressed EGFR signaling and inhibited phosphorylation of ERK and Akt. Metformin amplified this inhibitory effect and enhanced gefitinib-induced activation of AMPK signaling pathway. In vivo intravesical treatment of metformin and gefitinib on syngeneic orthotopic mice confirmed the significant inhibitory effect on bladder tumor growth. These two drugs may be an excellent combination for the treatment of bladder cancer through intravesical instillation. Bladder cancer is one of the most common cancers of the urinary tract in the world, accounting for about 74,000 new cases and 16,000 deaths in the United State in 2015 1 . Although radical cystectomy with chemotherapy has been applied for treating bladder cancer patients as the standard clinical administration and exerted efficient benefits, recurrence and metastasis take place frequently 2 . To prevent recurrence and progression, intravesical chemotherapy or immunosuppressive agents have been widely used after radical cystectomy 3 , 4 . Continue reading >>

Does Metformin Cause Cancer In Bladder?

Does Metformin Cause Cancer In Bladder?

Home Q & A Questions Does metformin cause cancer... while it may not be a known side effect, my mother in law took it and we just buried her from bladder cancer. My dad never smoked but he did take metformin for years (still is) and was just diagnosed with bladder cancer a couple months ago. Whether bladder cancer is a "Listed" side effect or not is not the issue. The issue is that many people are getting bladder cancer from the use of Metformin. I used Metformin for a few years for diabetes and fortunately discovered stage 1 bladder cancer accidentally when passing a kidney stone in April of 2012. The use of Metformin and the link to bladder cancer NEEDS to be investigated. we just buried my mother, she suffered from Transitional Cell Carcinoma of the bladder and kidneys, does metformin cause this type of cancer??? She was on it for years for type 2 diabetes I was diagnosed about 4 years ago with Bladder cancer and have had about 3 operations since then. Still have my bladder but I am still being treated for it. I took Metformin for several years and am wondering just how many people like me ended up with bladder cancer. Continue reading >>

Effectiveness Of Metformin In Protection Against Bladder Cancer

Effectiveness Of Metformin In Protection Against Bladder Cancer

Home / Specialties / Oncology / Effectiveness of Metformin in Protection against Bladder Cancer Effectiveness of Metformin in Protection against Bladder Cancer Researchers looked at whether exposure to metformin is associated with a decreased risk of bladder cancer. Metformin works to decrease blood glucose by activating AMP-activated protein kinase (AMPK), which occurs through the reduction of mammalian target of rapamycin (mTOR) signaling. This mechanism is also known to inhibit cancer cell growth and proliferation, meaning metformin may have an additional benefit of reducing cancer risk. Bladder cancer is known to require activation of the mTOR pathway, making metformin ideal for this type of cancer. Previous observational studies have found metformin to be associated with a decreased risk of other cancers, including cancers of the breast, colon, liver, lung, pancreas, and prostate, though certain biases may have resulted in an exaggeration of these associations. As bladder cancer occurs more commonly in patients with T2DM and there is limited data regarding the relationship between metformin and bladder cancer, a study by Mamtani, R. et al. was developed to examine the risk of bladder cancer in new users of metformin and sulfonylureas among a cohort of patients with T2DM not previously using these medications. This study was conducted using data from The Health Improvement Network (THIN), an electronic medical records database used in the UK. The database contains information for >10 million patients, making it ideal for rarer outcomes such as bladder cancer. This retrospective cohort study looked at patients that began using either metformin or a sulfonylurea between July 1, 2000 and August 31, 2010. Sulfonylureas were chosen as the comparator drugs in this study Continue reading >>

Metformin And The Risk Of Bladder Cancer In Patients With Type 2 Diabetes Mellitus And Its Treatment Efficacy: A Meta-analysis | Ding | Tumor

Metformin And The Risk Of Bladder Cancer In Patients With Type 2 Diabetes Mellitus And Its Treatment Efficacy: A Meta-analysis | Ding | Tumor

Metformin and the risk of bladder cancer in patients with type 2 diabetes mellitus and its treatment efficacy: a Meta-analysis Xian-fei DING, Meng-meng DOU, Xue-liang ZHOU, Li-feng LI, Chao-qi ZHANG, Feng WANG, Yan-yan CHI, Shao-xuan WU, Zhen-tao XU, Bo YUAN, Pei-na SHI, Shao-hua ZHENG, Zhi-rui FAN, Ya-na ZHANG, Jun WANG, Zhuan LV, Jun-sheng WANG, Yan-wu YU, Mou SUN, Tong-wen SUN, Qing-xia FAN Objective: To evaluate the association of the metformin therapy with the risk of bladder cancer and treatment efficacy in patients with type 2 diabetes mellitus.Methods: A computer-based online search was performed by using PubMed, Embase, Cochrane Library, ISI Web of Science and China National Knowledge Infrastructure (CNKI) databases. According to the inclusion and exclusion criteria, the literatures about metformin and the risk, and treatment efficacy of bladder cancer in patients with type 2 diabetes mellitus were selected. The primary end points included the incidence, cancer-specific mortality and recurrence-free survival. The outcome measures were hazard ratio (HR) with 95% confidence interval (95% CI) for the association between the metformin and the survival of bladder cancer patients. The Meta-analysis was performed using STATA 12.0 software.Results: A total of eight cohort studies involving 942 055 patients were included in this Meta-analysis. The present analysis showed that metformin therapy reduced the incidence of bladder cancer in patients with type 2 diabetes mellitus by 24% (HR = 0.76, 95% CI: 0.59-0.98, P = 0.032), and reduced the bladder cancer-specific mortality in patients by 22% (HR = 0.78, 95% CI: 0.61-1.00, P = 0.049), but didnt increase the risk of recurrence survival in type 2 diabetes patients with bladder cancer (HR = 0.70, 95% CI: 0.44-1.10, P = 0.12 Continue reading >>

Does Anyone Take Metformin?

Does Anyone Take Metformin?

2 years 11 months ago - 2 years 11 months ago #48685 by sweetheart238 Dear yoksgrl, i'm too but after 4 months taking Metformin bladder tumor was developed . Agree with you that cancer is the emperor of all maladies Please Log in or Create an account to join the conversation. 2 years 11 months ago #48666 by rocksteady This just may be a coincidence but I had symptom of burning upon urination. I saw my doctor and a urologist.I felt it was caused by something in my diet or meds. I also happened to have started metformin approx 6 months earlier. Before my cystoscope, I stopped metformin because of stomach/ digestive problems. Of course, the burning stopped almost immediately. I told the urologist about it and he just said 'that's good'. The burning came back when I had BCG,so much that I could barely hold it in for 15 minutes but eventually stopped after about the 4th installation. They still haven't told what caused the burning...enlarged prostate, CIS or something else ( like metformin). So I don't know if the metformin played a role, but seeing all these complaints and questions really makes me wonder. btw, it really lowered my A1C Please Log in or Create an account to join the conversation. 2 years 11 months ago #48604 by Harrymack I have been taking metformin for more than 12 years now and January of 2014 I was diagnosed with bladder cancer (5 tumors) after passing blood in urine along with frequent and painful urination for quite some time prior to being diagnosed. I went through 6 treatments of BCG and was clear of cancer for 9 months. Now at 12 months, 2 tumors have recurred that were more aggressive than the previous ones. I recently had the two removed surgically. I am convinced that, after extensive research on the Web, there's a link between metformin and blad Continue reading >>

Metformin Can Block Precancerous Progression To Invasive Tumors Of Bladder Through Inhibiting Stat3-mediated Signaling Pathways

Metformin Can Block Precancerous Progression To Invasive Tumors Of Bladder Through Inhibiting Stat3-mediated Signaling Pathways

Background: Metformin is the first line of oral antidiabetic drug in the biguanide class for treatment of type 2 diabetes. Increasing evidence has suggested that it is a potential anti-tumor drug. However, the mechanisms underlying inhibiting tumor development remain elusive, especially in bladder tumors. Methods: T24 and J82 cell lines were used as an in vitro model, and 24 female SD rats were used to build an N-methyl-N-nitrosourea (MNU)-induced orthotopic rat bladder cancer model. Transfection of lentivirus-based shRNA was used to construct the STAT3-KNOCKDOWN T24 cell line. After metformin treatment, the viability of bladde cancer cells was determined by CCK8. Cell cycle distribution and apoptosis were assessed by flow cytometry. The migration and invasion abilities of cells were evaluated by wound healing and transwell asssays. The inactivation of stat3 pahtway was examined by qRTPCR, western blot and Immunofluorescence. Results: Metformin can effectively inhibit precancerous progression to invasive cancer in an MNU-induced rat orthotopic bladder tumor model, although it could not completely suppress normal cells transforming into tumor cells. While the MNU could induce 50 % rats (4/8) to develop invasive bladder cancers, the rats co-administrated with metformin failed to develop invasive tumors but retained at precancerous or non-invasive stages, exhibiting as dysplasia, papillary tumor and/or carcinoma in situ (CIS). Accordingly, phosphorylation of signal transducer and activator of transcription 3 (STAT3), which is a well known oncogene, was significantly inhibited in the tumors of rats treated with metformin. In vitro experiments revealed that the metformin could efficiently inhibit STAT3 activation, which was associated with the cell cycle arrest, reduction o Continue reading >>

Bladder Cancer Link Seen Again With A Diabetes Drug

Bladder Cancer Link Seen Again With A Diabetes Drug

Home / Conditions / Type 2 Diabetes / Bladder Cancer Link Seen Again With A Diabetes Drug Bladder Cancer Link Seen Again With A Diabetes Drug While the risk remains low overall, a new large study showed a greater risk for pioglitazone than other diabetes drugs. Researchers looked at about 146,000 patients in the U.K. who had recently started taking an anti-diabetic drug; those on pioglitazone faced an increased risk of bladder cancer of 121.0 versus 88.9 per 100,000 person-years among those on other diabetes drugs (hazard ratio 1.63, 95% CI 1.22-2.19). Fifty-four patients receiving pioglitazone were diagnosed with cancer after a mean follow-up of 4.7 years. According to lead author Marco Tuccori, PhD, at the Jewish General Hospital in Montreal, Canada, the increased risk was not a class effect. But those on rosiglitazone (Avandia) didnt see an increased risk of bladder cancer (HR 1.10, 95% CI 0.83-1.47). Last year, Actos manufacturer Takeda agreed to pay $2.4 billion to settle lawsuits alleging that it hid from patients bladder cancer risks associated with the drug. Pioglitazone, an antidiabetic drug belonging to the thiazolidinedione class, has been shown to improve glycemic levels in people with type 2 diabetes. However, in 2005, the PROactive randomized controlled trial unexpectedly showed an imbalance in the number of cases of bladder cancer with pioglitazone compared with placebo. In contrast, this imbalance was never observed in randomized controlled trials of rosiglitazone, the other approved drug belonging to the thiazolidinedione class. The findings of the PROactive trial were subsequently corroborated in some, but not all, observational studies. Indeed, in the five-year interim analysis of a large observational study using the Kaiser Permanente Northern Calif Continue reading >>

Metformin May Have A Protective Effect In Bladder Cancer Patients

Metformin May Have A Protective Effect In Bladder Cancer Patients

Metformin May Have a Protective Effect in Bladder Cancer Patients Metformin May Have a Protective Effect in Bladder Cancer Patients Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug. Metformin use may decrease the risk of grade progression in patients with non-muscle invasive bladder cancer (NMIBC), according to study findings presented at the Canadian Urological Association 2016 annual meeting in Vancouver. Samer L. Traboulsi, MD, and colleagues at McGill University Health Centre in Montreal conducted a retrospective analysis of 1,356 NMIBC patients with a median age of 69.5 years. The cohort consisted of 1,197 patients (88.3%) without diabetes, 93 patients (6.9%) with diabetes on metformin, and 66 patients (4.9%) with diabetes and not on metformin who served as a reference group. In multivariate analysis, metformin use was not associated with disease recurrence and stage and disease progression, but it was associated with a significant 68% decreased risk of grade progression compared with the reference group. In addition, patients without diabetes had a significant 42% lower risk for disease progression compared with the reference group. Metformin is hypothesized to have antineoplastic activity due to its inhibitor activity on mammalian target of rapamycin, the researchers explained in a poster presentation. Investigations in clinical trials are needed to show whether metformin mitigates the deleterious effect of diabetes on stage progression, Dr. Traboulsi's group concluded. Previously, in a paper published in Urologic Oncology (2015;33:386.e7-386.e13), Canadian researchers reported on a study of 421 patients undergoing radical cystectomy for bladder cancer showing that metformin users had a 6 Continue reading >>

No Bladder-cancer Protection With Metformin, New Study Finds

No Bladder-cancer Protection With Metformin, New Study Finds

No Bladder-Cancer Protection With Metformin, New Study Finds The most commonly used medication for type 2 diabetes, metformin, may not offer protection from bladder cancer, the findings of a new cohort study suggest. Previous observational studies have linked metformin use with a reduction in cancer of the breast, colon , liver, lung , and pancreas , and 2 recent meta-analyses have shown an overall 30% reduction in all cancers with metformin compared with other diabetes medications. However, few data are available for bladder cancer, say Ronac Mamtani, MD, attending physician, hematology-oncology, Philadelphia Veterans Affairs Medical Center, Pennsylvania, and colleagues in their article, published online February 4 in Diabetes Care. Bladder cancer in particular is important both because people with type 2 diabetes have about a 40% increased risk of developing it and because another diabetes drug, the thiazolidinedione pioglitazone, has been linked with a possible increased risk . Use of metformin was not associated with a significantly decreased risk for bladder cancer at a median follow-up of about 2 years in the new study (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.60 1.09), say the authors. "In the UK's Health Improvement Network (THIN) patient population, we found no evidence for a decreased risk of bladder cancer in type 2 diabetes patients using metformin," they write. But Peter T. Donnan, PhD, professor of epidemiology and biostatistics, population health sciences, University of Dundee, and codirector of Tayside Clinical Trials Unit, Scotland, disagrees. "The findings indicate a 19% reduction in hazard for bladder cancer associated with use of metformin. The value of the HR is not inconsistent with previous findings in individual studies as well a Continue reading >>

Pioglitazone And Metformin (oral Route)

Pioglitazone And Metformin (oral Route)

Precautions Drug information provided by: Micromedex It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood and urine tests may be needed to check for unwanted effects. Check with your doctor right away if you start having chest pain; shortness of breath; excessive swelling of the hands, wrist, ankles, or feet; or if you are rapidly gaining weight. These may be symptoms of a serious heart problem. Let your doctor or dentist know you are taking this medicine. Your doctor may advise you to stop taking this medicine before you have major surgery or diagnostic tests, especially tests that use a contrast dye. Under certain conditions, too much metformin can cause a serious condition called lactic acidosis. The symptoms of lactic acidosis are severe and appear quickly. Lactic acidosis usually occurs when other serious health problems are present, such as a heart attack or kidney failure. The symptoms of lactic acidosis include: abdominal or stomach discomfort; decreased appetite; diarrhea; fast or shallow breathing; a general feeling of discomfort; muscle pain or cramping; and unusual sleepiness, tiredness, or weakness. If you have more than one of these symptoms together, you should get immediate emergency medical help. Tell your doctor right away if you have any of these symptoms: loss of appetite, nausea, vomiting, stomach pain, unusual tiredness or weakness, weight loss, or yellow eyes or skin. These may be symptoms of a serious liver problem. Check with your doctor right away if blurred vision, decreased vision, or any other change in vision occurs while you are taking this medicine. Your doctor may want you to have your eyes checked by an ophthalmologist (eye doctor). Certain women may be at Continue reading >>

Diabetes Drug Linked To Increased Bladder Cancer Risk

Diabetes Drug Linked To Increased Bladder Cancer Risk

Diabetes drug linked to increased bladder cancer risk Diabetes drug linked to increased bladder cancer risk "The anti-diabetic drug pioglitazone raises the risk of bladder cancer by 63 per cent," The Daily Telegraph reports. While the actual increased risk in real-world terms is small, the results may help to inform prescription decisions for both doctors and patients. Pioglitazone is a drug that helps people with type 2 diabetes by making their cells more sensitive to insulin. Some previous studies have linked pioglitazone with a raised chance of bladder cancer , although the results ofprevious research have been inconclusive. The new study looked at what happened to 145,806 people who took pioglitazone compared to other oral diabetes drugs (not insulin) over a 14-year period (2000 to 2014). Researchers found that people who had taken pioglitazone, as opposed to other diabetes drugs, were 63% more likely to have been diagnosed with bladder cancer, and that the risk increased the longer they had taken it. It is important to note that the overall risk of bladder cancer was low. There were 121 cases of bladder cancer for every 10,000 people taking pioglitazone for 10 years, compared to 89 cases for people taking other diabetes drugs. For people who respond well to this drug, the benefits in terms of diabetes control are thought to outweigh the risks. Anyone taking pioglitazone should continue the drug as prescribed, but discuss any concerns they have with their doctor, and immediately report any symptoms such as blood in urine, frequent urination, or pain when passing urine. The study was carried out by researchers from the Jewish General Hospital and McGill University, both in Montreal, Canada, and was funded by the Canadian Institutes of Health Research. The study was Continue reading >>

Very Common Diabetes Drug Raises Risk Of Bladder Cancer

Very Common Diabetes Drug Raises Risk Of Bladder Cancer

Very Common Diabetes Drug Raises Risk Of Bladder Cancer New research published in the Journal of the National Cancer Institute has found that a popular class of diabetes drug increases people's risk of developing bladder cancer. According to researchers from the Perelman School of Medicine at the University of Pennsylvania, the drug that accounts for up to 20% of the medication prescribed to diabetics in the U.S., thiazolidinedione (TZDs), gives patients a 2 to 3 times greater likelihood of developing bladder cancer than those taking a sulfonylurea drug, another common class of medication for diabetics. Diabetes patients are already known to have a slightly greater chance of developing this cancer as compared to the general population, which the authors suggest makes this finding especially important. About 40 out of 100,00 diabetics typically eventually develop cancer of the bladder, versus 30 in 100,000 out of the general population. Sixty thousand type 2 diabetics from the Health Improvement Network (THIN) database in the United Kingdom were observed in the study. Authors found that people treated with the TZD drugs, pioglitazone (Actos) or rosiglitzaone (Avandia), had a 2 to 3 fold increase in the risk of bladder cancer after 5 or more years taking the drug, as opposed to those who took sulfonylurea drugs, like glipizide (Glucotrol). The experts' analysis showed that 170 patients per 100,000 taking TZDs, for 5 or more years, were expected to develop this disease. For those taking sulfonylurea drugs, about 60 in 100,000 would develop bladder cancer. Ronac Mamtani, MD, the study's lead author, an instructor in the division of Hematology-Oncology in Penn's Abramson Cancer Center, explained: "Diabetes is one the most common chronic diseases worldwide, affecting 285 mil Continue reading >>

New Insight For Metformin Against Bladder Cancer

New Insight For Metformin Against Bladder Cancer

New insight for metformin against bladder cancer 1Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt 2CAS-TWAS Fellowship at University of Science and Technology of China (USTC), Hefei, 23027 China 1Pharmacology and Toxicology Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt 2CAS-TWAS Fellowship at University of Science and Technology of China (USTC), Hefei, 23027 China Amr Ahmed EL-Arabey, Email: [email protected] , Email: [email protected]_lerma . Received 2016 Oct 30; Accepted 2017 Feb 3. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated. International Agency for Research on Cancer (IARC) estimated that bladder cancer is the ninth most common cancer in the world, with 430,000 new cases and 165,000 deaths in 2012. Bladder cancer represents the fourth most common cancer in men and ninth most common cancer in women. It is the second most prevalent cancer in men 60years of age or older in United States. Looking further down, continuing advancements in cancer research could potentially offer more choices for clinician and patient with longer survival and better quality of life. Although, bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies; there are limited studies about application of metformin in the man Continue reading >>

Most Recent Papers With The Keyword Bladder Cancer Metformin | Read By Qxmd

Most Recent Papers With The Keyword Bladder Cancer Metformin | Read By Qxmd

Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer. Qiongli Su, Ting Tao, Lei Tang, Jun Deng, Kwame Oteng Darko, Sichun Zhou, Mei Peng, Shanping He, Qing Zeng, Alex F Chen, Xiaoping Yang Pyruvate kinase M2 (PKM2) regulates the final step of glycolysis levels that are correlated with the sensitivity of anticancer chemotherapeutic drugs. THP is one of the major drugs used in non-muscle-invasive bladder cancer instillation chemotherapy. However, low response ratio of THP (19.7%) treatment to human genitourinary tumours using collagen gel matrix has been observed. This study aims to investigate the effect of down-regulation of PKM2 on THP efficiency. Via inhibitor or siRNA, the effects of reduced PKM2 on the efficiency of THP were determined in 2 human and 1 murine bladder cancer cell lines, using MTT, cologenic and fluorescence approaches... Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis. Patrick O Richard, Ardalan E Ahmad, Shaheena Bashir, Alexandre Zlotta, Bimal Bhindi, Ricardo Leao, Madhur Nayan, Aza Mohammed, Neil E Fleshner, Girish S Kulkarni INTRODUCTION: Non-muscle invasive bladder cancer (NMIBC) accounts for 75-85% of all bladder cancers (UBC). Many UBC patients are also afflicted by diabetes mellitus (DM). It has been postulated that several oral hypoglycemic agents could impact disease-specific survival (DSS), but the data are sparse among NMIBC patients. Our primary objective was to evaluate the impact of metformin on DSS and overall survival (OS) in NMIBC patients. METHODS: This is a retrospective, population-based study that used linked administrative databases to identify diabetic patients 66 years who were subsequently diagnosed with NM Continue reading >>

More in diabetes